Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line... To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered every 4 weeks and to gain more insight into the pharmacokinetics and pharmacodynamics of this combination in previously untreated ovarian cancer patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of clinical oncology : official journal of the American Society of Clinical Oncology Pubmed

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

Huizing, M T; van Warmerdam, L J; Rosing, H; Schaefers, M C; Lai, A; Helmerhorst, T J; Veenhof, C H; Birkhofer, M J; Rodenhuis, S; Beijnen, J H; ten Bokkel Huinink, W W
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , Volume 15 (5): -1888 – Jun 16, 1997
Download PDF

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.


Abstract

To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered every 4 weeks and to gain more insight into the pharmacokinetics and pharmacodynamics of this combination in previously untreated ovarian cancer patients.

Loading next page...
 
/lp/pubmed/phase-i-and-pharmacologic-study-of-the-combination-paclitaxel-and-5yZIcN0JFW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0732-183X
DOI
10.1200/JCO.1997.15.5.1953
pmid
9164207

Abstract

To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered every 4 weeks and to gain more insight into the pharmacokinetics and pharmacodynamics of this combination in previously untreated ovarian cancer patients.

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology – Pubmed

Published: Jun 16, 1997

There are no references for this article.